Monitoring cellular immune responses to cancer immunotherapy

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 1, 2001, Pages 45-52

  Morse, M A ^a   Clay, T M ^a   Hobeika, A C ^a   Mosca, P J ^a   Lyerly, H K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CTL; ELISPOT; Immunological monitoring; Immunotherapy; Intracellular cytokine

Indexed keywords

BINDING PROTEIN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHROMIUM; CYTOKINE; DNA; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; HLA A1 ANTIGEN; HLA A2 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOSTIMULATING AGENT; LIPOCORTIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; PEPTIDE DERIVATIVE; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; TETRAMER; THYMIDINE; THYMIDINE DERIVATIVE; TRITIUM; TUMOR ANTIGEN; TUMOR VACCINE; UNINDEXED DRUG;

ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG RESEARCH; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOLOGICAL MONITORING; IMMUNOREACTIVITY; IMMUNOSTIMULATION; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

ANIMALS; CLINICAL TRIALS; COMPLEMENTARITY DETERMINING REGIONS; CYTOKINES; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; IMMUNOASSAY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES;

TRITIUM;

EID: 0035109747     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Direct visualization of antigen-specific CD8+ T-cells during the primary immune response to Epstein-Barr virus in vivo
2. Rapid determination of Epstein-Barr virus-specific CD8(+) T-cell frequencies by flow cytometry
3. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens
4. Infusion of cytotoxic T-cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
5. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T-cells
6. High frequencies of circulating melanoma-reactive CD8+ T-cells in patients with advanced melanoma
7. Use of a skin test assay to determine tumor-specific CD8+ T-cell reactivity
8. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor transfer
9. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study
10. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
11. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T-cells and induces regression of some metastases in advanced stage IV melanoma
12. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
13. Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor
14. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization
15. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
16. Melanoma-reactive human cytotoxic T-lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line
17. Longitudinal analysis of T-cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T-lymphocyte clones reveals a limited TCR repertoire
18. Quantitation of T-cell receptor frequencies by competitive PCR: Generation and evaluation of novel TCR subfamily and clone specific competitors
19. Immunological issues in vaccine trials: T-cell responses
20. Overexpression of the T-cell receptor β-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas
21. T-cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T-lymphocyte (CTL) clones: Tumor-infiltrating lymphocytes overexpress in melanocyte-lineage-specific CTL clone
22. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes
23. Phenotypic analysis of antigen-specific T-lymphocytes
24. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers
25. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity
26. Increased vaccine-specific T-cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
27. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T-lymphocytes
28. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
29. A re-evaluation of the frequency of CD8+ T-cells specific for EBV in healthy virus carriers
30. Distinct T-cell interactions with HLA class II tetramers characterize a spectrum of TCR affinities in the human antigen-specific T-cell response
31. High frequencies of naive Melan-A/MART-1-specific CD8(+) T-cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
32. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent
33. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors
34. Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer
35. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine
36. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
37. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens
38. Evaluation of the interferon-γ ELISPOT-assay for quantification of peptide specific T-lymphocytes from peripheral blood
39. Quantification of antigen specific CD8+ T-cells using an ELISPOT assay
40. Stimulation of CD8+ T-cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine
41. Development of a dual color enzyme-linked immunospot assay for simultaneous detection of murine T-helper type 1- and T-helper type 2-cells
42. Analysis of the T-cell response to tumor and viral peptide antigens by an IFN-γ ELISPOT assay
43. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay
44. Quantitation of antigen-reactive T-cells in peripheral blood by IFNγ-ELISPOT assay and chromium-release assay: A four-centre comparative trial
45. Determination of antigen-specific memory/effector CD4+ T-cell frequencies by flow cytometry: Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency
46. Detection of antigen-specific T-cell cytokine expression in whole blood by flow cytometry
47. Identification of functional subsets by flow cytometry: Intracellular detection of cytokine expression
48. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased of intracellular interleukin-2 in peripheral blood lymphocytes
49. Evaluation of immunological response in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines - Preliminary report
50. Real time quantitative PCR
51. Quantification of cytokine mRNA expression by RT-PCR in samples of previously frozen blood
52. Functional analysis of antigen-specific T-lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
53. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical phase I study
54. Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical phase I study
55. Circulating Melan-A/Mart-1 specific cytolytic T-lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype
56. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
57. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2
58. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
59. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine